Patents Assigned to Shionogi & Co., Ltd.
  • Patent number: 11911394
    Abstract: The present invention relates to a method for preventing transmission of influenza, wherein said method comprises administering an effective amount of a compound to a patient having an influenza virus infection, herein referred to as “index patient”, wherein the compound has one of the formulae (I) and (II), or its pharmaceutically acceptable salt. The compound to be used in the present invention reduces infectivity of the influenza virus of the index patient, and therefore, reduces the risk of the index patient to trigger an influenza epidemic or an influenza pandemic as compared to a control patient.
    Type: Grant
    Filed: December 23, 2021
    Date of Patent: February 27, 2024
    Assignees: Shionogi & Co., Ltd.
    Inventors: Takeshi Noshi, Takahiro Noda, Ryu Yoshida, Takao Shishido, Kaoru Baba, Aeron C. Hurt, Leo Yi Yang Lee, Steffen Wildum, Klaus Kuhlbusch, Barry Clinch, Jan Michal Nebesky, Annabelle Lemenuel, Wendy S. Barclay, Jean-Eric Charoin, Yoshinori Ando
  • Patent number: 11897899
    Abstract: Novel compounds having D3 receptor antagonistic activity are provided. A compound represented by formula (I): wherein ring A is a heterocycle, X1 is each independently CR4aR4b, X2 is each independently CR4cR4d, Y1 and Y2 are each independently a carbon atom or a nitrogen atom, L is —N(R6)—C(?O)— or the like, W is cyclyl or the like, R2 and R3 are each independently substituted or unsubstituted alkyl or the like, R1a, R1b, R4a to R4d, and R6 are each independently hydrogen atoms or the like, p is 1 or 2, q is an integer of 1 to 3, n is an integer of 1 to 4, s is an integer of 0 to 4, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: April 21, 2022
    Date of Patent: February 13, 2024
    Assignee: SHIONOGI & CO., LTD.
    Inventors: Hiroyuki Tobinaga, Koji Masuda, Masanao Inagaki, Manami Masuda
  • Patent number: 11883407
    Abstract: Provided is a pharmaceutical composition for treating chronic cough, which has substantially no side effects of taste disturbance. A pharmaceutical composition for treating chronic cough, comprising a compound represented by Formula (I): or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: October 4, 2019
    Date of Patent: January 30, 2024
    Assignee: SHIONOGI & CO., LTD.
    Inventors: Ryuta Tamano, Erika Kasai, Sayaka Miyazaki, Katsue Magari
  • Publication number: 20230382893
    Abstract: The present invention provides a compound represented by formula (I): wherein the dashed line indicates the presence or absence of a bond; R1 is carboxy or the like; L is substituted or unsubstituted non-aromatic carbocyclyldiyl or the like; R2 is substituted or unsubstituted alkyl; R3 is a hydrogen atom or the like; X is ?CRX— or ?N—; Y is ?CRY— or ?N—; U is —CRU? or —N?; V is —CRV? or —N?; W is ?CRW— or ?N—; ZA is —C? or —N—; ZB is —CR5R6— or the like; ZC is —CR7R8— or the like; RX, RY, RV and RW are each independently a hydrogen atom or the like; RU is a hydrogen atom or the like; R5 and R6 are each independently a hydrogen atom or the like; R7 and R8 are each independently a hydrogen atom or the like; R4 is substituted or unsubstituted alkyloxy or the like, or a pharmaceutically acceptable salt thereof, having an antiviral activity; and a pharmaceutical composition comprising the same.
    Type: Application
    Filed: October 27, 2021
    Publication date: November 30, 2023
    Applicants: Shionogi & Co., Ltd., UBE Corporation
    Inventors: Azusa OKANO, Yusuke TATENO, Kouhei NODU, Shinji SUZUKI, Toshiyuki AKIYAMA, Masaaki MATOYAMA, Hirota AKAZA, Takashi FUKUDA
  • Patent number: 11814368
    Abstract: The present invention provides a compound exhibiting coronavirus 3 CL protease inhibitory activity or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the same. Furthermore, the present invention provides a crystalline form useful as an active pharmaceutical ingredient, and a pharmaceutical composition comprising the same. A compound represented by Formula: or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: April 29, 2022
    Date of Patent: November 14, 2023
    Assignees: SHIONOGI & CO., LTD., NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY
    Inventors: Yuki Tachibana, Shota Uehara, Yuto Unoh, Kenji Nakahara, Yoshiyuki Taoda, Yukiko Yamatsu, Shigeru Ando, Michihito Sasaki
  • Patent number: 11807648
    Abstract: The present invention provides a process for preparing a compound of the formula (II): wherein R2 is unsubstituted alkyl, characterized by reacting a compound of the formula (I): wherein R1 is hydrogen or a protecting group other than unsubstituted alkyl, with a compound of the formula: R2—OH, wherein R2 is as defined above, in the presence of a sodium salt and/or a magnesium salt.
    Type: Grant
    Filed: January 19, 2022
    Date of Patent: November 7, 2023
    Assignee: SHIONOGI & CO., LTD.
    Inventor: Setsuya Shibahara
  • Publication number: 20230321251
    Abstract: By administering a liposome formulation in which an antibacterial agent is bound to a liposome, in particular, a lipid-soluble side chain of the antibacterial agent is bound to a lipid of the liposome, and the antibacterial agent extends outward from a surface of the liposome, it is possible to provide a liposome formulation in which blood retention of an active ingredient is increased, an amount of the active ingredient taken by a reticuloendothelial system such as a liver is reduced, an amount of the active ingredient transferred into a kidney is reduced, and antibacterial activity can also be increased with little resistance.
    Type: Application
    Filed: September 3, 2021
    Publication date: October 12, 2023
    Applicants: OSAKA UNIVERSITY, Shionogi & Co., Ltd.
    Inventors: Takashi MATSUZAKI, Hideki MAKI, Osamu YOSHIDA, Tomoyuki HOMMA
  • Publication number: 20230293036
    Abstract: An estimation system obtains brain wave measurement data and functional magnetic resonance imaging measurement data simultaneously measured from a subject, calculates first functional connectivity for each channel combination based on correlation between channels included in the brain wave measurement data, calculates second functional connectivity for each brain network based on correlation between regions of interest included in the functional magnetic resonance imaging measurement data, calculates a disorder-likelihood label by calculating a score representing disorder-likelihood to be estimated with the use of a plurality of second functional connectivities, and determines an estimation model for estimating disorder-likelihood based on prescribed first functional connectivity by machine learning using the first functional connectivity for each channel combination and the disorder-likelihood label.
    Type: Application
    Filed: July 1, 2021
    Publication date: September 21, 2023
    Applicants: ADVANCED TELECOMMUNICATIONS RESEARCH INSTITUTE INTERNATIONAL, SHIONOGI & CO., LTD.
    Inventors: Takeshi OGAWA, Ryuta TAMANO, Motoaki KAWANABE, Mitsuo KAWATO
  • Publication number: 20230284983
    Abstract: There is provided a therapy selection support device that generates a discriminator (identifier) as a diagnostic marker or a classifier as a stratification marker through machine learning on the basis of measurement data on brain activities and that uses the discriminator or the classifier as a biomarker. A therapy selection support system 300a, 300b, 500 includes a clustering device 300b that executes stratification in which the results of measurement of brain functional connectivity correlation values acquired from a plurality of second subjects are divided into a plurality of clusters through a clustering process.
    Type: Application
    Filed: July 15, 2021
    Publication date: September 14, 2023
    Applicants: ADVANCED TELECOMMUNICATIONS RESEARCH INSTITUTE INTERNATIONAL, HIROSHIMA UNIVERSITY, SHIONOGI & CO., LTD.
    Inventors: Yuto KASHIWAGI, Tomoki TOKUDA, Yuji TAKAHARA, Mitsuo KAWATO, Ayumu YAMASHITA, Okito YAMASHITA, Yuki SAKAI, Junichiro YOSHIMOTO, Go OKADA
  • Publication number: 20230287004
    Abstract: The present invention provides the following compounds having anti-viral activity. A1 is CR1AR1B, S or O; A2 is CR2AR2B, S or O; A3 is CR3AR3B, S or O; A4 is CR4AR4B, S or O; the number of hetero atoms among atoms constituting the ring which consists of A1, A2, A3, A4, nitrogen atom adjacent to A1 and carbon atom adjacent to A1, is 1 or 2; R1A and R1B are each independently hydrogen, halogen, alkyl, or the like; R2A and R2B are each independently hydrogen, halogen, alkyl, or the like; R3A and R3B are each independently hydrogen, halogen, alkyl, or the like; R4A and R4B are each independently hydrogen, halogen, alkyl, or the like; R3A and R3B may be taken together to form non-aromatic carbocycle or non-aromatic heterocycle; X is CH2, S or O; R1 is each independently halogen, hydroxy, or the like; m is any integer of 0 to 2; and n is any integer of 1 to 2.
    Type: Application
    Filed: December 13, 2022
    Publication date: September 14, 2023
    Applicant: Shionogi & Co., Ltd.
    Inventors: Makoto KAWAI, Kenji TOMITA, Toshiyuki AKIYAMA, Azusa OKANO, Masayoshi MIYAGAWA
  • Publication number: 20230278960
    Abstract: The present invention provides novel aclidinium salt of the formula (I) and a process for the production of the aclidinium salt. wherein R1 is C1-C6 alkyl or C1-C6 alkyloxy; R2 is hydrogen or C1-C6 alkyloxy; R3 is hydrogen, halogen, C1-C6 alkyl or C1-C6 alkyloxy; R4 is hydrogen, C1-C6 alkyloxy, halo C1-C6 alkyloxy or C1-C6 alkylamino; R5 is C1-C3 alkyl; and X? is an anion.
    Type: Application
    Filed: May 11, 2023
    Publication date: September 7, 2023
    Applicants: Shionogi & Co., Ltd., SHIONOGI PHARMA CO., LTD.
    Inventor: Shohei MAJIMA
  • Publication number: 20230256092
    Abstract: The combined use of an anti-CCR8 antibody and a chemotherapeutic agent was found to be useful in the treatment or prevention of cancer.
    Type: Application
    Filed: June 30, 2021
    Publication date: August 17, 2023
    Applicant: Shionogi & Co., Ltd.
    Inventors: Hidekazu Tanaka, Wataru Nogami, Ryohei Nagai, Yudai Sonoda
  • Publication number: 20230227454
    Abstract: The present invention provides a compound represented by Formula (I): wherein ring A is a substituted or unsubstituted heterocycle; ring C is a benzene ring or the like; R1 is halogen or the like; R2a and R2b are each independently hydrogen or the like; R3 is substituted or unsubstituted alkyl or the like; R4 is hydrogen or the like; and n is an integer of 1 to 3.
    Type: Application
    Filed: March 22, 2023
    Publication date: July 20, 2023
    Applicant: Shionogi & Co., Ltd.
    Inventors: Yoshiyuki TAODA, Yuto UNOH
  • Publication number: 20230212154
    Abstract: The present invention provides a compound exhibiting coronavirus 3CL protease inhibitory activity or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the same. Furthermore, the present invention provides a crystalline form useful as an active pharmaceutical ingredient, and a pharmaceutical composition comprising the same. A compound represented by Formula: , or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: April 29, 2022
    Publication date: July 6, 2023
    Applicants: Shionogi & Co., Ltd., NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY
    Inventors: Yuki TACHIBANA, Shota UEHARA, Yuto UNOH, Kenji NAKAHARA, Yoshiyuki TAODA, Yukiko YAMATSU, Shigeru ANDO, Michihito SASAKI
  • Publication number: 20230210822
    Abstract: Provided is a pharmaceutical composition for treating and/or preventing fatty liver disease, particularly nonalcoholic fatty liver disease, the pharmaceutical composition having an excellent ACC2-selective inhibitory action and having no side effects such as an increase in plasma triglyceride or a decrease in platelet concentration. A pharmaceutical composition for treating and/or preventing fatty liver disease, the pharmaceutical composition comprising a compound represented by Formula (I): wherein R1 is haloalkyl or non-aromatic carbocyclyl, R2 is a hydrogen atom or halogen, R3 is halogen, ring A is a group represented by the formula: -L1- is —O—(CH2)—, —(CH2)2—, or the like, R4 is alkyl or haloalkyl, and R5 is alkylcarbonyl or carbamoyl, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: May 20, 2021
    Publication date: July 6, 2023
    Applicant: Shionogi & Co., Ltd.
    Inventors: Hideo YUKIOKA, Atsuyuki SHIMAZAKI, Tadateru HAMADA, Naoki OHYABU
  • Patent number: 11685740
    Abstract: Provided are a novel compound having an antagonistic activity for the P2X7 receptor, and a pharmaceutical composition having an antagonistic activity for the P2X7 receptor.
    Type: Grant
    Filed: June 16, 2021
    Date of Patent: June 27, 2023
    Assignee: Shionogi & Co., Ltd.
    Inventors: Koji Masuda, Shuichi Sugiyama, Toru Yamada, Eiichi Kojima, Tomoyuki Ogawa, Naotake Kobayashi, Hiroyuki Kai
  • Publication number: 20230190174
    Abstract: The signal processing apparatus receives an input acoustic signal, and amplitude-modulates the received input acoustic signal to generate an output acoustic signal having an amplitude change corresponding to a frequency of a gamma wave, and outputs the generated output acoustic signal.
    Type: Application
    Filed: February 21, 2023
    Publication date: June 22, 2023
    Applicants: Pixie Dust Technologies, Inc., Shionogi & Co., Ltd.
    Inventors: Yoshiki NAGATANI, Kazuki TAKAZAWA, Koichi OGAWA, Kazuma MAEDA, Tatsuya YANAGAWA
  • Publication number: 20230190173
    Abstract: A signal processing apparatus receives an input acoustic signal, acquires a first acoustic signal having a periodic variation corresponding to the frequency of gamma waves, and outputs an output acoustic signal based on the acquired first acoustic signal and the second acoustic signal. The second acoustic signal is based on the input acoustic signal.
    Type: Application
    Filed: February 16, 2023
    Publication date: June 22, 2023
    Applicants: Pixie Dust Technologies, Inc., Shionogi & Co., Ltd.
    Inventors: Yoshiki NAGATANI, Kazuki TAKAZAWA, Koichi OGAWA, Kazuma MAEDA
  • Publication number: 20230183205
    Abstract: By wet-pulverizing a compound represented by Formula (I), a pharmaceutically acceptable salt thereof, or a solvate thereof (hereinafter referred to as a compound represented by Formula (I) or the like), it is possible to provide a crystal of the compound represented by Formula (I) or the like and a pharmaceutical composition containing the same having excellent stability. In addition, by wet-kneading and/or wet-granulating the compound represented by Formula (I) or the like, it is possible to provide a pharmaceutical composition containing the compound represented by Formula (I) or the like having excellent stability.
    Type: Application
    Filed: May 13, 2021
    Publication date: June 15, 2023
    Applicant: Shionogi & Co., Ltd.
    Inventors: Yuya OCHII, Chika NISHIDA, Go KIMURA, Shinichi ODA, Shohei MAJIMA, Takahiro OSHIMA
  • Publication number: 20230173027
    Abstract: A pharmaceutical composition containing the substance according to any one of the following (a) to (c), an organic acid, a metal salt of an organic acid, and a sugar and/or a sugar alcohol, wherein when the pharmaceutical composition is dissolved in distilled water for injection, a pH of the pharmaceutical composition is 3.0 to 4.
    Type: Application
    Filed: April 19, 2021
    Publication date: June 8, 2023
    Applicants: Shionogi & Co., Ltd., StemRim Inc.
    Inventors: Nao MATSUOKA, Shuichi HATANO, Yuya KUGA, Maki OKABE, Takehiko YAMAZAKI, Koichi YOKOTA